Global Echinocandins Market: Overview
Echinocandin is a new class of antifugal agents that work by inhibiting cell wall synthesis. These agents act by inhibiting β-1, 3-glucan synthase complex. Caspofungin is the first approved echinocandin candidate. Caspofungin was approved by the U.S. FDA for the treatment of invasive candidiasis in patients resistant to other antifungal agents, empirical therapy in febrile neutropenia, esophageal candidiasis, and certain forms of candidemia. Echinocandins offer several advantages over other antifungal agents. The potential benefits of echinocandins include less risk of drug–drug interactions, novel mechanism of action, and lower incidence of adverse effects.
Global Echinocandins Market: Key Trends
The global echinocandins market is projected to grow at a rapid pace during the forecast period. Echinocandins have been studied extensively and offer advantages such as broad spectrum of activity including strains of fungi resistant to other antifungal agents and fewer side effects with no hepatotoxicity and nephrotoxicity compared to macrolide and azole antifungals. The expanding indications of echinocandins in secondary fungal infections have shown promising results which is expected to drive the global echinocandins market.
Global Echinocandins Market: Segmentation
The global echinocandins market can be segmented based on drug type, indication, and region. In terms of drug type, the market can be classified into caspofungin, micafungin, and anidulafungin. Based on indication, the global echinocandins market can be categorized into esophageal candidiasis, candidemia with invasive candidiasis, febrile neutropenia, invasive aspergillosis, and others. In terms of region, the global echinocandins market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Candidemia is a major cause of mortality in immunosuppressed patients due to rise in invasive fungal infections. These patients show reduced susceptibility to azole antifungals. Fluconazole has been the mainstay of the treatment of candedimia patients; however, it is losing ground due to increase in resistance among Candida species. Moreover, aspergillosis is a major contributor of morbidity in patients with hematological malignancies and those undergoing transplants. Amphotericin B used against invasive fungal infections leads to nephrotoxicity and high incidence of infusion related adverse effects. Introduction of echinocandins against this backdrop is a promising development in antifungal armamentarium.
Global Echinocandins Market: Regional Analysis
North America is projected to account for the largest share of the global market in terms of revenue during the forecast period. High research and development activities in the field of antifungal drugs, ongoing clinical trials with echinocandins, and increase in incidence of fungal infections in the region are the major factors attributed to the high market share of the region. According to the U.S. Department of Health & Human Services, invasive candidiasis is one of the common health care-associated infection. Around 46,000 cases of invasive candidiasis are reported in the U.S. each year. Europe is anticipated to account for the second largest share of the global market owing to high awareness among people about the treatment options and rise in prevalence of chronic diseases. Asia Pacific is expected to witness strong growth during the forecast period. Rise in government initiatives to improve health care, increase in geriatric population, surge in disposable income, and high investment by key players in the emerging markets in Asia Pacific are likely to fuel the growth of the echinocandins market in the region.
Global Echinocandins Market: Competitive Landscape
The global echinocandins market is highly fragmented due to presence of large number of global as well as new players. Major players operating in the market are Alkem Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Mylan N.V., Merck & Co., Inc., Fresenius SE & Co. KGaA, Xellia Pharmaceuticals, and MSD Pharmaceuticals Pvt. Ltd.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.